SCHEMBL4127446

SCHEMBL4127446

Cc1ccc(S(=O)(=O)NC(=O)Cc2ccc(NC3=NC(=O)C(=Cc4ccc(C)c(-n5cccc5)c4)S3)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 8/20 0.41
ERBB2 P04626 7/20 0.41
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
ADRB2 P07550 1/20 0.37
ADRB1 P08588 1/20 0.37
ADRB3 P13945 1/20 0.37
HPGD P15428 3/20 0.36
POLB P06746 3/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 2/20 0.36
RECQL P46063 1/20 0.36
BCL2 P10415 1/20 0.36
BCL2L1 Q07817 1/20 0.36
MCL1 Q07820 1/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALOX5 P09917 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4139742 0.86 EGFR (0.45) EGFRERBB2KMT2AMEN1ADRB2
SCHEMBL4122971 0.86 EGFR (0.45) EGFRERBB2KMT2AMEN1ADRB2
SCHEMBL4122964 0.85 EGFR (0.44) EGFRERBB2KMT2AMEN1ADRB2
SCHEMBL4122968 0.85 EGFR (0.44) EGFRERBB2KMT2AMEN1ADRB2
SCHEMBL4125379 0.84 BCL2 (0.49) EGFRERBB2KMT2AMEN1BCL2
SCHEMBL4125381 0.84 BCL2 (0.49) EGFRERBB2KMT2AMEN1BCL2
SCHEMBL4127449 0.84 EGFR (0.39) EGFRERBB2KMT2AMEN1ADRB2
SCHEMBL4666500 0.83 EGFR (0.40) EGFRERBB2KMT2AMEN1ADRB2
SCHEMBL4277628 0.83 BCL2 (0.48) EGFRERBB2KMT2AMEN1BCL2
SCHEMBL4277634 0.83 BCL2 (0.48) EGFRERBB2KMT2AMEN1BCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ EGFR 729/4885ERBB2 138/4885KMT2A 2895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.